Journal of Cancer Research and Clinical Oncology

, Volume 135, Issue 1, pp 53–59

Serum-soluble interleukin-2 receptor (sIL-2R) is an extremely strong prognostic factor for patients with peripheral T-cell lymphoma, unspecified (PTCL-U)

Authors

  • Jun-ichi Kitagawa
    • First Department of Internal MedicineGifu University Graduate School of Medicine
  • Takeshi Hara
    • First Department of Internal MedicineGifu University Graduate School of Medicine
    • First Department of Internal MedicineGifu University Graduate School of Medicine
  • Naoe Goto
    • First Department of Internal MedicineGifu University Graduate School of Medicine
  • Nobuhiro Kanemura
    • First Department of Internal MedicineGifu University Graduate School of Medicine
  • Takeshi Yoshikawa
    • Division of HematologyGifu Municipal Hospital
  • Senji Kasahara
    • First Department of Internal MedicineGifu University Graduate School of Medicine
  • Toshiki Yamada
    • First Department of Internal MedicineGifu University Graduate School of Medicine
  • Michio Sawada
    • First Department of Internal MedicineGifu University Graduate School of Medicine
  • Takeshi Takahashi
    • Division of HematologyGifu Municipal Hospital
  • Masahito Shimizu
    • First Department of Internal MedicineGifu University Graduate School of Medicine
  • Tsuyoshi Takami
    • Department of ImmunopathologyGifu University Graduate School of Medicine
  • Hisataka Moriwaki
    • First Department of Internal MedicineGifu University Graduate School of Medicine
Original Paper

DOI: 10.1007/s00432-008-0440-0

Cite this article as:
Kitagawa, J., Hara, T., Tsurumi, H. et al. J Cancer Res Clin Oncol (2009) 135: 53. doi:10.1007/s00432-008-0440-0

Abstract

Purpose

The aim of this study was to assess the prognostic factors of peripheral T-cell lymphoma, unspecified (PTCL-U).

Patients and methods

We retrospectively analyzed 30 cases fulfilling the criteria of PTCL-U defined by the World Health Organization classification. The patients were treated with 6–8 cycles of a CHOP or THP (pirarubicin)-COP regimen.

Results

A high serum sIL-2R level (≥2,000 U/ml) at onset was associated with a low complete remission rate. Patients with high sIL-2R had significantly lower survival rates (5 year, 15.1%) than those with low sIL-2R (<2,000 U/ml) (100%) (P < 0.005). Factors associated with worse overall survival in a univariate analysis were high sIL-2R (P < 0.005), high age (>60 years) (P < 0.05), poor performance status (P < 0.01) and poor international prognostic index (P < 0.05). No correlation was observed between sIL-2R and other markers. Multivariate analysis showed that only sIL-2R was a prognostic factor for overall survival (P < 0.01).

Conclusion

The results suggest that a high serum sIL-2R level predicts a poor prognosis in PTCL-U.

Keywords

Peripheral T-cell lymphoma (PTCL)Soluble interleukin-2 receptor (sIL-2R)Prognostic analysis

Copyright information

© Springer-Verlag 2008